Abstract
Plasma cell leukemia is an aggressive variant of multiple myeloma affecting 4% of all cases of the latter. It is characterized by the presence of at least 20% plasma cells circulating in the peripheral blood, equivalent to an absolute number greater than 2,000/mm3. Plasma cell leukemia exits in two forms: primary or de novo plasma cell leukemia (60%) and the secondary form, which consists of a leukemia transformation of a multiple myeloma (40% plasma cell leukemia and 1% multiple myeloma). The disease is rare and has poor prognosis, as there is no effective therapy except the standard melphalan–prednisone combination. We report here on a case of primary plasma cell leukemia diagnosed in the Nice University Hospital’s Onco-hematology Department, which achieved complete response (CR) after eight cycles of bortezomib-cexamethasone followed by maintenance treatment with bortezomib.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Guièze R, Moreau A, Dupire S et al (2005) Leucémie à Plasmocytes. Hématologie 3:217–225
Saccaro S, Fonseca R, Veillon D et al (2005) Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 78:288–294
Musto P, Rossini F, Gay F et al (2007) Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 109(11):2285–2290
Kim SJ, Kim J, Cho Y et al (2007) Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. J Clin Oncol 37(5):382–384
Katodritou E, Verrou E, Gastari V et al (2007) Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 32(7):1153–1156
Woodruff RK, Malpas JS, Paxton AM et al (1978) Plasma cell leukaemia (PCL): a report on 15 patients. Blood 52:839–845
Toma VA, Retief FP, Potgieter GM, Anderson JD (1980) Plasma cell leukaemia: diagnostic problems in our experience with 11 cases. Acta haemato 163:136–145
Noel P, Kyle RA (1987) Plasma cell leukaemia: an evaluation of response to therapy. Am J Med 83(6):1062–1068
Bernasconi C, Castelli G, Pagnucco G et al (1989) Plasma cell leukemia: a report on 15 patients. Eur J Haematol (supplement) 51:76–83
Dimopoulos MA, Palumbo A, Delasalle KB et al (1994) Primary plasma cell leukaemia. Br J Haematol 88:754–759
Garcia-Sanz R, Orfao A, Gonzales M et al (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93:1032–1037
Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Divinι M et al (2001) Primary plasma cell leukemia: a report of 18 cases. Leuk Res 25:103–107
Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A et al (2002) Intermediate doses of melphalan for the treatment of primary plasma cell leukaemia. Ann Hematol 81:362–367
Conflict of interest statement
The authors declare that they do not have any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fraimout, N., Kadouch, B., Ticchioni, M. et al. Plasma cell leukemia: advantages of treatment with bortezomib. Targ Oncol 3, 265–267 (2008). https://doi.org/10.1007/s11523-008-0096-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-008-0096-3